Welcome to our dedicated page for ADC Therapeutics SA SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics amended its royalty financing with entities managed by HealthCare Royalty Management and issued new equity-linked securities. HCR has funded the Company with $300 million to date. Under the amended agreement, a change of control now triggers a payment to HCR of $150 million if it occurs on or before December 31, 2027, or $200 million if it occurs on or after January 1, 2028. Royalty payments continue after a change of control until reaching the Royalty Cap, unless bought out for $525 million on or before December 31, 2029 or $750 million on or after January 1, 2030, in each case reduced by prior royalties and the change of control payment.
In connection with this amendment, the Company issued HCR warrants to purchase 9,834,776 common shares at an exercise price of $3.8130 per share, exercisable until December 31, 2030. The warrants allow cash or cashless exercise, contain change-of-control mechanics that accelerate or transfer the warrants, restrict transferability until December 31, 2027, and include registration rights requiring the Company to file a resale registration statement for the underlying shares. The warrants were issued as an unregistered private offering under Section 4(a)(2) of the Securities Act.
ADC Therapeutics SA reported that Chief Accounting Officer Lisa Michelle Kallebo received a grant of 62,900 Common Shares on February 13, 2026 as a restricted share unit award valued at $3.99 per share. These shares vest in three equal installments: one-third on the first anniversary of the grant date and one-third on each of the following two anniversaries, subject to continued service. On the same date, 5,433 Common Shares were withheld by the company at $3.99 per share to cover her tax obligations from previously vesting restricted share units. After these transactions, she directly owned 128,224 Common Shares.
ADC Therapeutics SA Chief Medical Officer Receives Equity Award
ADC Therapeutics SA granted Chief Medical Officer Zaki Mohamed an award covering 285,200 Common Shares on February 13, 2026. According to the footnotes, these shares will be delivered upon settlement of restricted share units that vest one-third on the first anniversary of the grant date and one-third on each anniversary thereafter, subject to continued service.
On the same date, 24,603 Common Shares were withheld by the company to cover Mr. Mohamed’s tax withholding obligations related to previously granted restricted share units that vested. After these transactions, he directly owned 682,417 Common Shares.
ADC Therapeutics SA reported that Chief Legal Officer Peter J. Graham received a grant of 294,800 Common Shares on February 13, 2026, valued at $3.99 per share. These shares relate to a restricted share unit award that vests in three equal annual installments beginning on the first anniversary of the grant date, subject to continued service.
The company also withheld 33,294 Common Shares at $3.99 per share to cover Mr. Graham’s tax obligations upon vesting of previously granted restricted share units, which is a non‑market tax-withholding disposition rather than an open-market sale. Following these transactions, Mr. Graham directly holds 620,540 Common Shares.
ADC Therapeutics SA Chief Financial Officer Jose Carmona reported equity-related transactions in company common shares. He was granted 271,600 common shares at $3.99 per share as part of a restricted share unit award that vests in three equal annual installments starting on February 13, 2027, contingent on continued service. To cover tax withholding from the vesting of previously granted restricted share units, 25,880 common shares were withheld by the company at $3.99 per share. After these transactions, Carmona directly holds 734,376 common shares.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik acquired 900,000 Common Shares on February 13, 2026 as part of a restricted share unit award valued at $3.99 per share. According to a footnote, these shares will be delivered over time as the RSUs vest: one-third on the first anniversary of the February 13, 2026 grant date and one-third on each of the next two anniversaries, subject to continued service.
On the same date, 103,231 Common Shares were disposed of through a tax-withholding transaction at $3.99 per share to cover Mr. Mallik’s tax obligations related to previously granted RSUs vesting. After these transactions, he directly held 1,446,769 Common Shares. A separate indirect holding of 669,101 Common Shares is reported as held by a grantor retained annuity trust, and Mr. Mallik disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
ADC Therapeutics received an amended Schedule 13G showing updated ownership by OrbiMed investment entities as of 12/31/2025. OrbiMed Advisors LLC reports beneficial ownership of 2,592,057 common shares, representing 2.1% of the class, with shared voting and dispositive power over these shares.
OrbiMed Capital LLC reports beneficial ownership of 3,230,797 common shares, representing 2.6% of the class, with sole voting and dispositive power. Together, the reporting persons hold an aggregate 4.7% of ADC Therapeutics’ common shares on behalf of other persons entitled to dividends or sale proceeds. They certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
ADC Therapeutics SA received an updated ownership report showing that investment entities affiliated with Point72, including Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen, beneficially owned 5,014,617 common shares, representing 4.0% of the company’s common shares as of December 31, 2025.
The filing states these entities have shared voting and dispositive power over all reported shares, held through an investment fund managed by Point72 Asset Management. The reporting persons certify the shares were not acquired or held to change or influence control of ADC Therapeutics.
ADC Therapeutics SA received a Schedule 13G from TCG Crossover Fund II and related parties reporting a significant passive stake. The reporting persons collectively beneficially own 11,390,175 common shares, representing 9.2% of the outstanding common shares.
The shares are held of record by TCG Crossover Fund II, with TCG Crossover GP II as general partner and Chen Yu as sole managing member, giving them shared voting and dispositive power. The ownership percentage is based on 123,877,111 common shares outstanding as of October 31, 2025. The filers certify the holdings are not for the purpose of changing or influencing control of ADC Therapeutics.
Redmile Group and affiliates report a significant passive stake in ADC Therapeutics. Redmile Group, Jeremy C. Green and RedCo II Master Fund jointly report beneficial ownership of 15,666,731 common shares, representing 12.7% of ADC Therapeutics’ common stock, based on 123,877,111 shares outstanding as of October 31, 2025.
Within this, RedCo II Master Fund, L.P. is attributed 13,145,712 shares, or 10.6% of the class. The group also holds pre-funded warrants that could deliver up to 27,743,685 additional shares for certain Redmile clients, including 22,445,224 for RedCo II, but these are blocked from exercise above a 9.99% ownership threshold.
The filers certify the securities were not acquired and are not held to change or influence control of ADC Therapeutics, indicating a passive investment intent under Schedule 13G/A.